Reproterol
Reproterol
Chemical compound
Reproterol is a short-acting[1] β2 adrenoreceptor agonist used in the treatment of asthma.[2]
Quick Facts Clinical data, AHFS/Drugs.com ...
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Inhalation (MDI), IV |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.053.579 |
Chemical and physical data | |
Formula | C18H23N5O5 |
Molar mass | 389.412 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
It was patented in 1965 and came into medical use in 1977.[3]
Reproterol contains a stereocenter and is chiral. There are thus two enantiomers, the (R)-form and the (S)-form. The commercial preparations contain the drug as a racemate, an equal mixture of the two enantiomers.[4]
- Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 54X. ISBN 9783527607495.
- Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Vol. 57. Frankfurt/Main: Rote Liste Service GmbH. 2017. p. 196. ISBN 978-3-946057-10-9.
This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |